Table 5.
Suspended and put on hold clinical trials with PD-1/PD-L1 inhibitors in multiple myeloma.
| Title | N | Con. | Experimental arm | Identifier Phase |
|---|---|---|---|---|
| Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) | 43 | NDMM RRMM |
Pembrolizumab/Lenalidomide/Dexamethasone |
NCT02906332 2 suspended |
| Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) | 640 | NDMM | a) Lenalidomide/Dexamethasone b) Pembrolizumab/Lenalidomide/Dexamethasone |
NCT02579863 3 suspended |
| Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) | 300 | RRMM | a) Pembrolizumab/Pomalidomide/Dexamethasone b) Pomalidomide/Dexamethasone |
NCT02576977 3 suspended |
| An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, With or Without Pomalidomide and Dexamethasone, in Patients With Multiple Myeloma |
375 | RRMM | a) Nivolumab b) Nivolumab/Ipilimumab§ c) Nivolumab/Daratumumab d) Nivolumab/Daratumumab/ Pomalidomide/Dexamethasone |
NCT01592370 1 put on hold (enrolment resumed) |
| A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumabin Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide | 95 | RRMM | a) Elotuzumab/Pomalidamide/Dexamethasone b) Nivolumab/Elotuzumab |
NCT02612779 2 put on hold (enrolment resumed) |
| An Investigational Immuno-therapy Study of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma (CheckMate 602) | 406 | RRMM | a) Nivolumab/Pomalidomide/Dexamethasone b) Pomalidomide/Dexamethasone c) Nivolumab/Elotuzumab/ Pomalidomide/Dexamethasone |
NCT02726581 3 put on hold |
| Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM) | 288 | RRMM | a) Atezolizumab b) c*) Atezolizumab/Lenalidomide d) Atezolizumab/Daratumumab e) Atezolizumab/Daratumumab/Lenalidomide f) Atezolizumab/Daratumumab/Pomalidomide |
NCT02431208 1 put on hold (enrolment resumed) |
| Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma | 20 | SMM | Atezolizumab |
NCT02784483 1 suspended |
| A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma | 138 | RRMM | a) Durvalumab b) Durvalumab/Pomalidomide c) Durvalumab/Pomalidomide/Dexamethasone |
NCT02616640 1 put on hold |
| A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma | 138 | NDMM | a) Durvalumab/Lenalidomide b) Durvalumab/Lenalidomide/Dexamethasone |
NCT02685826 1 suspended |
| A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003) | 144 | RRMM | a) Durvalumab/Daratumumab b) Durvalumab/Daratumumab/ Pomalidomid/Dexamethasone |
NCT02807454 2 put on hold |
| A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005) | 180 | RRMM | Durvalumab/Daratumumab |
NCT03000452 2 suspended |
N - estimated enrolment; Con. - condition; RRMM - relapsed or refractory multiple myeloma; NDMM - newly diagnosed multiple myeloma; SMM - smoldering myeloma; mAb - monoclonal antibody; Pembrolizumab - mAb anti-PD-1; Pidilizumab - mAb anti-PD-1; Nivolumab - mAb anti-PD-1; Atezolizumab - mAb anti-PD-L1; Durvalumab - mAb anti-PD-L1.